Due to these discoveries, the first oral AR PROTAC degrader for prostate cancer was created, and despite anticipated pharmacokinetic difficulties such as poor cell permeability and limited bioavailability, it has shown promise in clinical testing. This evidence concerns the gene AR and Familial prostate cancer.